The tyrosine kinase receptor EphB4 interacts with its ephrinB2 ligand to act as a bi-directional signaling system that mediates adhesion, migration and guidance by controlling attractive and repulsive activities. 
Introduction
The British pathologist Stephen Paget observed as early as 1889 that the distribution pattern of many metastatic tumors does not follow a random pattern that can be explained by trapping of metastasizing tumor cells (TC) in a distant blood or lymphatic vessel bed (1) . Instead, many tumors appear to "home" preferentially to certain organs. These observations led Paget to develop the "seed-and-soil theory" of tumor spread and metastasis (1, 2) . According to this theory, the metastasizing tumor cell (the "seed") needs to fall onto a fertile "soil" in order to grow. Pioneering animal experiments in the nineteen seventies provided experimental evidence for Paget's theory by establishing the various subclones of the B16 melanoma as a model to study the mechanisms of site-specific metastasis (3, 4) . Chemokines (5), endothelial cell adhesion molecules (6, 7) and organ-selectively expressed growth factors (8, 9) have subsequently been implicated in controlling site-specific metastasis. Comparative transcriptomic analyses of primary tumors and metastases have in contributed to the definition of gene signatures associated with the metastatic phenotype, including signatures of preferential metastasis to specific organs such as the lungs (10) (11) (12) . Yet, the molecular mechanisms behind Paget's seed-and-soil theory remain largely unresolved to this day.
EphB tyrosine kinase receptors and their transmembrane ephrinB ligands have been identified as a bidirectional signaling system that transduces guidance cues on outgrowing axons and sprouting endothelial cells (13) (14) (15) . As such, EphB/ephrinB interactions contribute to network formation in the neuronal system as well as in the vascular system. The receptor EphB4 is widely expressed by human tumor cell lines (16, 17) . Correspondingly, a strong correlation between EphB4 expression and increased invasiveness has been reported for breast, colon, bladder, prostate and endometrial tumors as well as for mesothelioma (17) (18) (19) (20) . Manipulatory experiments have demonstrated pro-tumorigenic functions of tumor cell expressed EphB4 in different tumor models (17, 18, 21) . A pro-tumorigenic role of EphB4 could be inferred from its stimulating effects on tumor angiogenesis by activating ephrinB2 reverse signaling (22, 23) . In contrast, recent reports also suggest a role of EphB4 as a tumor suppressor gene in experimental colorectal tumors which appears to be supported by expression profiling data in human colorectal tumors (24) . Similarly, increased EphB4 phosphorylation inhibits tumorigenicity in mammary tumors (16) . These 7 ephrinB2 stimulation (Fig. 1D ). Likewise, EphB4 or ΔC-EphB4 expression did not affect the cells' ability to establish three dimensional spheroids or to grow colonies in soft agar ( Fig. 2A) .
To assess the cells' migratory capacity, we performed in vitro scratch assays. Monolayers of A375 EphB4, A375 ΔC-EphB4, and A375 mock cells were scratch wounded and wound closure was monitored after 24 h. Both, full length EphB4 and truncated EphB4 expressing A375 ΔC-EphB4 cells migrated significantly faster than A375 mock cells (Fig. 2B) suggesting that the extracellular domain of EphB4 is sufficient for a pro-migratory phenotype of A375 melanoma cells. Stimulation with clustered recombinant human Fc or ephrinB2-Fc did not change A375 migration confirming that the pro-migratory effect of EphB4 is independent of forward signaling (data not shown). Furthermore, we tested the chemotactic properties of transduced A375 cells in a transmigration assay. A375 ΔC-EphB4 and EphB4 cells migrated faster through gelatin coated-filters compared to mock cells (Fig. 2C , black bars). This increased migration was not significantly affected by stimulation with ephrinB2-Fc (Fig. 2C , grey bars) or after seeding the cells on different matrices, e.g. type IV collagen, fibronectin, or Matrigel (Suppl. Fig. 1 ).
Changes in migratory capacity were not associated with changes in the cells' proteolytic activity as confirmed by MMP-2 and MMP-9 activities in gelatin-zymograms (Suppl Fig. 2 ).
EphB4 expression exerts a pro-adhesive phenotype on tumor cells in vitro
Bi-directional signaling between EphB4 and ephrinB2 has been reported to transduce both, attractive as well as repulsive signals on contacting cells. We consequently tested the ability of EphB4 expressing A375 cells to adhere to ephrinB2 expressing endothelial cells. The number of A375 EphB4 and A375 ΔC-EphB4 expressing cells, which adhered to HUVEC monolayers expressing either full length ephrinB2 or ∆C-ephrinB2 was significantly increased compared to A375 mock cells (Fig. 3A) . As shown in Fig. 1B, ephrinB2-Fc stimulation induced the internalization of cell surface EphB4 or ΔC-EphB4. To assess the specificity of EphB4/ephrinB2-mediated tumor cell adhesion to endothelial cells, tumor cells were pre-incubated with ephrinB2-Fc prior to allowing them to adhere to HUVEC. EphrinB2-Fc stimulation of the A375 EphB4 variants dramatically reduced the ability of A375 to adhere to ephrinB2 or to ΔC-ephrinB2 expressing HUVEC (Fig. 3B) . Correspondingly, we blocked the adhesion of A375 EphB4 or ΔC- expressing HUVEC in flow chamber experiments (Fig. 3E) . Adhesion of EphB4 expressing cells could be completely blocked by EphB4-Fc (Fig. 3E) . Importantly, ΔC-EphB4 cells adhered much more weakly to ephrinB2 expressing HUVEC under flow than full length EphB4 transfectants indicating that firm adhesion to endothelial cells is EphB4 forward signaling dependent (Fig. 3E ).
In order to directly quantify the adhesive strength mediated by the interaction between ephrinB2 and EphB4, we performed single cell force spectroscopy experiments (SCFS) by atomic force microscopy (AFM). Single, cantilever bound A375 EphB4, A375 ΔC-EphB4 or A375 mock cells were used to probe HUVEC ephrinB2 (Fig. 4) . The maximum unbinding force between A375 cells and HUVEC reached a plateau within 120 s of adhesion time (data not shown). Thus, an adhesion time of 60 s was used for all subsequent measurements. The average maximum unbinding force and average unbinding work of A375
EphB4 and A375 ΔC-EphB4 cells were significantly higher than observed in A375 mock cells (Fig. 4B, C) .
Taken together, these experiments show that the extracellular domains of EphB4 and ephrinB2 support strong tumor cell adhesion to endothelial cells. (Fig. 5A ). These titration experiments were also performed to scale the system in order to translate later luciferase measurements into absolute cell numbers.
EphB4 mediates tumor cell adhesion to ephrinB2 expressing endothelium in vivo
Luciferase expressing tumor cells were injected into the arterial blood flow. Mice were sacrificed 1 h after arterial injection of the A375 EphB4, A375 ΔC-EphB4 and A375 mock cells. The 1 h time point was selected on the basis of preliminary experiments revealing that cell distribution within the first minutes predominately reflected relative tissue perfusion and not specific homing. The inguinal lymph nodes, lungs, heart, liver, spleen, intestine, colon, kidneys, muscle, brain, and the left femur (bone) were harvested and homogenized, and luciferase activity was measured in each of these organs. The highest luciferase activities were measured in the most vascularized organs (i.e., lungs, liver, kidneys, brain and heart) ( Fig. 5B ). However, significantly more A375 EphB4 cells were detected in the lungs, the liver and the kidneys compared to A375 mock and A375 ΔC-EphB4 (Fig. 5B ).
To assess the specificity of the observed EphB4-mediated tumor cell homing phenotype, we performed Preferential homing of A375 EphB4 cells and EphB4-Fc blocking strongly suggested a direct interaction of injected cells with endothelial cell expressed ephrinB2. We confirmed endothelial cell ephrinB2 expression in the lungs where it was expressed by a subset of microvessels (Fig. 6B ). Expression was mostly confined to small arteries and arterioles that were covered by αSMA-positive mural cells (Suppl. Fig. 3 ). EphrinB2 expression was also observed in kidney glomerular capillary endothelial cells as well as a subset of kidney arteriolar αSMA-positive and αSMA-negative microvessels (Suppl. Fig. 3 ). To validate more directly organ-specific differences in endothelial cell ephrinB2 expression, we isolated endothelial cells from mouse lung and heart and compared ephrinB2 protein expression. The lung and the heart were used for these experiments since A375 EphB4 cells preferentially home to the lung (see Fig. 5B ). Despite the strong vascularization of the heart, ephrinB2 protein was detected in endothelial cells isolated from lungs, but not in endothelial cells isolated from heart ( properties that enable them to complete each step of the metastatic process (2, 34) . A metastatic tumor cell must be capable to break away from the primary tumor, to induce angiogenesis, to invade lymphatic or blood vessels, to intravasate into the lumen of an invaded vessel, to survive the rigid biophysical forces of the circulation, to lodge and to adhere in the vasculature of a distant organ, to extravasate the vessel, to survive at the distant site, and it must eventually be capable of initiating growth at the secondary site which again includes the requirement to induce angiogenesis. Each of these steps of the metastatic cascade is considered rate-limiting for the process, making metastasis in fact a very inefficient biological process which is only accomplished by the large number of tumor cells that can be shed into the circulation from a primary tumor. Importantly, while a primary tumor may be capable of shedding large numbers of tumor cells, most of these may undergo apoptotic cell death and only few may have metastasis-initiating capacity (cancer stem cells?) (35, 36) . Likewise, metastatic dissemination of tumor cells may be a necessary albeit not sufficient requirement for the growth of tumor cells at distant sites since tumor dormancy mechanisms may be limiting for the formation of metastasis following metastatic dissemination (37) A critical step of the metastatic cascade is the lodging of systemically disseminating tumor cells at distant sites. Circulating tumor cells get trapped in the next capillary bed that they encounter. Yet, they may leave their primary site of lodging again if they are not retained by specific adhesive interactions to endothelial cells which is the first interface of a metastasizing tumor cell in a distant organ. In the present study we have addressed the specific hypothesis that tumor cells which express EphB4 may be involved in the metastatic homing to ephrinB2 expressing vascular beds. This was an attractive hypothesis given that most human tumors express EphB4 (17) (18) (19) (20) and that distinct endothelial cell populations express ephrinB2 on their luminal aspect (28) . Likewise, it has recently been reported that tumor cell expressed This study deliberately focused on the early steps of systemic tumor cell dissemination to trace the fate of tumor cells that were directly injected in the systemic arterial circulation. An arterial injection approach was applied to avoid the first-pass lung effect following the widely practiced tail vein injection technique.
The preferential homing phenotype of EphB4 expressing tumor cells was rapidly detectable and analyzed (Fig. 4B) . After capture, cantilever bound cells were incubated for 5 min before positioning them above single HUVEC. After bringing the cantilever bound cell into contact with the surface of a single HUVEC, the cells were loaded with a constant force of 800 pN (Fig. 4A ). Cells were allowed to interact for time intervals of up to 120 s before pulling them apart ("adhesion time").
Subsequently, a standard adhesion time of 60 s was used for all measurements. The delay between individual, successive force-distance measurements was 120 s. EphB4-Fc or control human Fc were 
